Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of EZR-104 in patients with stage-2 Hypertension

Trial Profile

Study of EZR-104 in patients with stage-2 Hypertension

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jan 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Valsartan (Primary)
  • Indications Hypertension
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Jan 2017 New trial record
    • 18 Jan 2017 According to an EZRA Innovations media release, the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for EZR-104. The NDA application was filed based on the clinical data from this and two pharmacokinetic studies. The Prescription Drug User Fee Act (PDUFA) goal date for NDA approval is September 10, 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top